Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adicet Bio, Inc. - Common Stock
(NQ:
ACET
)
4.970
-0.170 (-3.31%)
Delayed Quote
Updated: 9:45 AM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adicet Bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
January 08, 2025
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 31, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
December 19, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
December 18, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
November 18, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
November 18, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
November 16, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 06, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
November 05, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
November 01, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
October 16, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
September 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
September 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
September 19, 2024
From
Adicet Bio, Inc.
Via
Business Wire
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
↗
September 11, 2024
Via
Benzinga
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
August 19, 2024
From
Adicet Bio, Inc.
Via
Business Wire
ACET Stock Earnings: Adicet Bio Beats EPS for Q2 2024
↗
August 13, 2024
ACET stock results show that Adicet Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 13, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
August 01, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 31, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
July 08, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
June 24, 2024
From
Adicet Bio, Inc.
Via
Business Wire
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
↗
June 10, 2024
These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news
Via
InvestorPlace
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
June 05, 2024
From
Adicet Bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
